Patient education is a key obligation for doctors under the treatment contract. The expansion of the AOP catalogue (catalogue of operations that can be performed on an outpatient basis in accordance with Section 115b of the Fifth Book of the German Social Code (SGB V)) from January 2023 opens up new outpatient treatment options that tend to involve higher risks. This risk profile must be taken into account when informing patients.In any case, the timing of the information should be chosen so that the patient can give their consent in a well-considered manner. There is no fixed "blocking period" between information and consent, so the patient can consent immediately. In the case of high-risk procedures, the patient should be informed several days in advance. Criteria for determining the right time are the type and severity of the procedure, urgency and individual circumstances of the patient. The information provided should be complete and comprehensible, including the diagnosis, need for treatment, risks and alternatives. Comprehensive documentation of the information provided goes without saying.Telemedical counselling is possible in suitable cases, but the risk of timely and complete counselling remains with the doctor performing the procedure. In view of outpatient procedures that require follow-up care at home, the safety information should be more comprehensive.The expansion of the AOP catalogue opens up new opportunities for outpatient procedures, but harbours legal risks. Adapted risk and safety information is required, whereby telemedicine can optimise practice organisation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00113-023-01390-1 | DOI Listing |
Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM cohort, we compared the outcome of ide-cel ( = 162) versus cilta-cel ( = 42). Co-primary efficacy endpoints of the study were overall response rate (ORR) and progression-free survival (PFS).
View Article and Find Full Text PDFLeukemia
January 2025
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Chirurgie (Heidelb)
December 2024
Klinik und Poliklinik für Orthopädie, Unfallchirurgie und Plastische Chirurgie, Universitätsklinikum Leipzig AöR, Leipzig, Deutschland.
At the latest since the Medical Services Healthcare Insurance Reform Act (MDK), the declared will of the legislation is the conversion of operations previously carried out in an inpatient setting to an outpatient setting. In trauma surgery and orthopedics numerous operations are carried out that could principally also be performed in an outpatient setting; however, a prerequisite is a medical assessment of the suitability of patients as well as an economic and normative framework that makes outpatient surgery attractive. Both the Outpatient Surgery in Hospitals Catalogue (AOP-Katalog) and the first edition of the Hybrid Diagnosis-related Groups (DRG) define interventions in trauma surgery that could be carried out in an outpatient setting.
View Article and Find Full Text PDFAktuelle Urol
September 2024
Zentrum für künstliche Intelligenz, Universität zu Lübeck, Lübeck, Deutschland.
Background: The hospital reform initiated through an expert opinion of the German research institute IGES places great emphasis on the aspect of outpatient care. In this context, the current IGES guidelines extend further than has previously been the case. There are only very isolated instances where this theoretical potential has been translated into practical application in urology.
View Article and Find Full Text PDFBlood Adv
June 2024
Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most specific serum parameter.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!